Advanced search×

Seminars in Nuclear Medicine

Print ISSN
Electronic ISSN
Impact factor
Usage rank
Article count
Free count
Free percentage
PDFs via platforms
Gale, Sciencedirect from 1971, Proquest, and CSA

  1. Dose optimization in nuclear medicine.

    Seminars in Nuclear Medicine 44(3):193 (2014) PMID 24832584

    The practice of diagnostic nuclear medicine involves the use of ionizing radiation, and thus the potential risk associated with such exposure must be weighed against the benefits to the patient. This requires that the right test with the right dose be administered to the right patient at the right t...
  2. Musculoskeletal imaging using fluoride PET.

    Seminars in Nuclear Medicine 43(6):427 (2013) PMID 24094710

    The convenience of (18)F-fluoride imaging is undeniable both because of its favorable tracer and because of its technical characteristics, including high image quality and short examination times leading to increased patient comfort. Depending on the activity administered, the radiation dose to pati...
  3. Letter from the editors.

    Seminars in Nuclear Medicine 43(4):267 (2013) PMID 23725987

  4. Positron emission tomography in renal cell carcinoma: an imaging biomarker in development.

    Seminars in Nuclear Medicine 42(4):221 (2012) PMID 22681671

    We will start with a brief overview of the demographics, molecular pathogenesis, and evolving treatment strategies in RCC because this information is essential for better understanding of uptake of various PET radiotracers in this cancer and their indications. This will be followed by discussing the...
  5. Decreased sensitivity of (18)F-fluorodeoxyglucose imaging in infection and inflammation.

    Seminars in Nuclear Medicine 42(4):261 (2012) PMID 22681675

    Nuclear medicine plays an important role in the evaluation of inflammation and infection. Although (99m)Tc-methylene diphosphonate, (67)Ga-citrate, and in vitro labeled autologous leukocyte imaging are useful procedures, there are limitations to each of them. (18)F-fluorodeoxyglucose-positron-emissi...
  6. Concepts, consequences, and implications of theranosis.

    Seminars in Nuclear Medicine 42(3):147 (2012) PMID 22475423

    Although the term has been coined recently, the concepts underlying theranosis have been applied in patient care for more than one-half century. However, advanced technologies are used now. Theranosis describes processes used to tailor therapy for a patient. It is the use of diagnostic tests to iden...
  7. In Memoriam: Alexander Gottschalk, MD (1932-2010)

    Seminars in Nuclear Medicine 41(2):2 (2011) PMID 21272680

  8. Design of Clinical Trials

    Seminars in Nuclear Medicine 40(5):6 (2010) PMID 20674592

    Clinical trial design for nuclear medicine diagnostic imaging radiopharmaceuticals must include a design for preclinical safety studies. These studies should establish that the investigational product (IP) does not have a toxic effect. As a further requirement, radiopharmaceutical cl...
  9. Immuno-positron emission tomography in cancer models.

    Seminars in Nuclear Medicine 40(3):182 (2010) PMID 20350627 PMCID PMC2848398

    Positron emission tomography (PET) is playing an increasingly important role in the diagnosis, staging, and monitoring response to treatment in a variety of cancers. Recent efforts have focused on immuno-PET, which uses antibody-based radiotracers, to image tumors based on expression of tumor-associ...
  10. Seminars in Nuclear Medicine. Selected pharmacologic interventions and monitoring. Letter from the editors.

    Seminars in Nuclear Medicine 39(3):155 (2009) PMID 19341835